|
20 Apr 2022 |
Arcturus Announces Self-amplifying COVID-19 mRNA Vaccine Candidate ARCT-154 Meets Primary Efficacy Endpoint in Phase 3 Study
|
|
20 Apr 2022 |
Bavarian Nordic Announces Initiation of a Global Phase 3 Clinical Trial of its RSV Vaccine Candidate in Older Adults
|
|
18 Apr 2022 |
Emergex Provides an Update on First-in-Human Studies of Its Novel Dengue Fever and Coronavirus T cell Adaptive Vaccines
|
|
11 Apr 2022 |
Nouscom Announces New Translational Phase 1 Data of NOUS-209, an 'off-the-shelf' Neoantigen Cancer Vaccine for the Treatment of MSI-H Solid Tumors, at AACR 2022
|
|
30 Mar 2022 |
TolerogenixX Receives Approval to Start Phase IIb Trial for its Immune Tolerance-Inducing MIC-Lx Cell Therapy
|
|
30 Mar 2022 |
HDT Bio Doses First Healthy Volunteer in US Phase 1 Trial of Next Generation COVID-19 Variant RNA Vaccine
|
|
30 Mar 2022 |
Pfizer and BioNTech Receive Expanded U.S. Emergency Use Authorization for an Additional COVID-19 Vaccine Booster in Individuals Aged 50 Years and Older
|
|
29 Mar 2022 |
Provention Bio Announces Positive Final Results from First-In-Human Study of Coxsackievirus B Vaccine Candidate PRV-101
|
|
29 Mar 2022 |
CyanVac and Blue Lake Biotechnology Announce FDA Clearance of IND Application for BLB-201 Intranasal RSV Vaccine
|
|
19 Mar 2022 |
Moderna Submits Amendment to the Emergency Use Authorization for an Additional Booster Dose of its COVID-19 Vaccine in the U.S.
|
|
19 Mar 2022 |
Moderna's Omicron-specific bivalent booster candidate (mRNA-1273.214) combines Moderna's Omicron-specific booster candidate (mRNA-1273.529) and the Moderna COVID-19 vaccine (mRNA-1273)
|
|
19 Mar 2022 |
Moderna Announces First Participant Dosed in Phase 1 Study of its HIV Trimer mRNA Vaccine
|
|
16 Mar 2022 |
Pfizer and BioNTech Submit for U.S. Emergency Use Authorization of an Additional Booster Dose of their COVID-19 Vaccine for Older Adults
|
|
09 Mar 2022 |
BioNTech and Regeneron Expand Strategic Collaboration to Advance Clinical Development of FixVac and Libtayo® (cemiplimab) Combination in NSCLC
|
|
08 Mar 2022 |
Valneva Successfully Completes Pivotal Phase 3 Trial of Single-Shot Chikungunya Vaccine Candidate
|
|
05 Mar 2022 |
Aravax Pty Ltd announces opening of IND for Phase 2 clinical trials of PVX108, a next-generation immunotherapy for the treatment of peanut allergy
|
|
02 Mar 2022 |
Phase 3 CLOVER Trial for Pfizer’s Investigational Clostridioides Difficile Vaccine Indicates Strong Potential Effect in Reducing Duration and Severity of Disease Based on Secondary Endpoints
|
|
24 Feb 2022 |
Medicago and GSK announce the approval by Health Canada of COVIFENZ®, an Adjuvanted Plant-Based COVID-19 Vaccine
|
|
23 Feb 2022 |
Sanofi and GSK to seek regulatory authorization for COVID-19 vaccine
|
|
23 Feb 2022 |
Moderna Initiates Phase 3 Portion of Pivotal Trial for mRNA Respiratory Syncytial Virus (RSV) Vaccine Candidate, Following Independent Safety Review of Interim Data
|
|
21 Feb 2022 |
GSK provides update on phase III RSV maternal vaccine candidate programme
|
|
16 Feb 2022 |
European Medicines Agency Approves Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease and Pneumonia in Adults
|
|
16 Feb 2022 |
PharmaJet Partner Technovalia Announces Interim Results of Needle-free COVID-19 Vaccine Trial
|
|
16 Feb 2022 |
AC Immune ACI-35.030 Phase 1b/2a Trial Interim Data Confirm Consistent Safety and Potent Immunogenicity of pTau Alzheimer’s Vaccine in High-dose Cohort
|
|
12 Feb 2022 |
Vaxxinity’s COVID-19 Vaccine Candidate UB-612 Produces High Levels of Neutralizing Antibodies Against Omicron and Other Variants of Concern
|
